Preclinical evidence suggests that IL-6 might be involved in the initiation, as well as in the progression and maintenance of hypertension through a reduction in nitric oxide bioavailability, an increase in vascular superoxide, regulation of angiotensin II expression, and alterations in vascular function and structure. This evidence concerns the gene IL6 and hypertensive disorder.